Duke Human Vaccine Institute Receives Contract for Non-Human Primate Work
The Duke Human Vaccine Institute received a $5,362,962 (includes the base period and all options), seven-year (if all term options are exercised) contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to perform viral load assays for laboratories involved in HIV/AIDS research.
34 Duke researchers named among most influential scientists in world
Duke researchers make up one percent of the top one percent of researchers in their respective fields, according to a report released by Clarivate Analytics.
Duke Institute Tapped to Build a Rapid-Response System for Viral Pandemics
The Duke Human Vaccine Institute has received a $12.8 million, 30-month grant from the U.S. Department of Defense, Defense Advanced Research Projects Agency (DARPA) to develop a system capable of halting viral pandemics within 60 days.
Duke Human Vaccine Institute Receives Contract Renewal for Lab Oversight
The Duke Human Vaccine Institute received a renewal of a $41,463,666 (includes the base period and all options), seven-year (if all term options are exercised) contract from the National Institute of Allergy and Infectious Diseases to house quality assurance programs for laboratories involved in HIV/AIDS research.
WRAL: Duke researchers make strides in finding HIV vaccine
A research team led by Duke University scientists on Friday announced that it found clues in immune systems that could help develop an effective HIV vaccine.
Duke Among Sites to Train First Responders On Infectious Disease Safety
Duke Health is one of eight sites nationally selected to participate in a program to help train first responders and other workers in properly handling infectious disease emergencies.
DHVI-IVQAC Biorepository Receives Accreditation from College of American Pathologists
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to the Duke Human Vaccine Institute-Immunology Virology Quality Assessment Center’s (DHVI-IVQAC) biorepository based on the results of a recent on-site inspection as part of the CAP’s Accreditation Programs.
Duke Human Vaccine Team Awarded Up to $9 million To Study Fungal Fever
The Duke Human Vaccine Institute’s Vaccine and Treatment Evaluation Unit has received an initial award of approximately $5 million from the National Institute of Allergy and Infectious Diseases (NIAID) to support further research on Valley Fever Pneumonia.
DHVI-IVQAC Biorepository Receives Accreditation from College of American Pathologists
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to the Duke Human Vaccine Institute-Immunology Virology Quality Assessment Center’s (DHVI-IVQAC) biorepository based on the results of a recent on-site inspection as part of the CAP’s Accreditation Programs.